The Experts below are selected from a list of 6144 Experts worldwide ranked by ideXlab platform
Hikaru Koide - One of the best experts on this subject based on the ideXlab platform.
-
Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or Macroalbuminuria.
Diabetic Medicine, 2001Co-Authors: T. Nakamura, Chifuyu Ushiyama, Shigenobu Suzuki, N. Shimada, K. Sekizuka, L. Ebihara, Hikaru KoideAbstract:Summary Aims Troglitazone, a newly developed thiazolidinedione derivative, has been shown to ameliorate microalbuminuria in diabetic animal model and in human diabetic nephropathy in short-term studies. The aim of the present study was to determine whether troglitazone or sulphonylurea affect micro- albuminuria, Macroalbuminuria, or serum type IV collagen concentrations in patients with diabetic nephropathy. Methods We studied 32 normotensive patients with type 2 diabetes mellitus associated with microalbuminuria (n = 16) or Macroalbuminuria (n = 16) and 20 healthy controls. The patients were randomly assigned to one of two groups: those treated with glibenclamide (5.0 mg/day) (n = 8) and those treated with troglitazone (400 mg/day) (n = 8). They received the drug regimen for 12 months. Serum type IV collagen was measured with sandwich enzyme immunoassay. Results Type IV collagen concentrations in macroalbuminuric patients were higher than those in microalbuminuric patients (P
-
effect of troglitazone on urinary albumin excretion and serum type iv collagen concentrations in type 2 diabetic patients with microalbuminuria or Macroalbuminuria
Diabetic Medicine, 2001Co-Authors: T. Nakamura, Chifuyu Ushiyama, Shigenobu Suzuki, N. Shimada, K. Sekizuka, L. Ebihara, Hikaru KoideAbstract:Summary Aims Troglitazone, a newly developed thiazolidinedione derivative, has been shown to ameliorate microalbuminuria in diabetic animal model and in human diabetic nephropathy in short-term studies. The aim of the present study was to determine whether troglitazone or sulphonylurea affect micro- albuminuria, Macroalbuminuria, or serum type IV collagen concentrations in patients with diabetic nephropathy. Methods We studied 32 normotensive patients with type 2 diabetes mellitus associated with microalbuminuria (n = 16) or Macroalbuminuria (n = 16) and 20 healthy controls. The patients were randomly assigned to one of two groups: those treated with glibenclamide (5.0 mg/day) (n = 8) and those treated with troglitazone (400 mg/day) (n = 8). They received the drug regimen for 12 months. Serum type IV collagen was measured with sandwich enzyme immunoassay. Results Type IV collagen concentrations in macroalbuminuric patients were higher than those in microalbuminuric patients (P < 0.05) and healthy controls (P < 0.01). Troglitazone reduced urinary albumin excretion (UAE) in micro- albuminuric patients from 126 μg/min (range 58–180 μg/min) to 42 μg/min (range 14–80 μg/min) (P < 0.01) and also reduced serum type IV collagen levels gradually at 3, 6 and 12 months after treatment (P < 0.05). However, glibenclamide did not affect UAE and type IV collagen levels in micro- albuminuric diabetes patients. In addition, neither troglitazone nor gliben- clamide changed UAE and type IV collagen levels in macroalbuminuric patients. Conclusions These data suggest that troglitazone is an effective treatment for renal injury in patients with early diabetic nephropathy.
T. Nakamura - One of the best experts on this subject based on the ideXlab platform.
-
Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or Macroalbuminuria.
Diabetic Medicine, 2001Co-Authors: T. Nakamura, Chifuyu Ushiyama, Shigenobu Suzuki, N. Shimada, K. Sekizuka, L. Ebihara, Hikaru KoideAbstract:Summary Aims Troglitazone, a newly developed thiazolidinedione derivative, has been shown to ameliorate microalbuminuria in diabetic animal model and in human diabetic nephropathy in short-term studies. The aim of the present study was to determine whether troglitazone or sulphonylurea affect micro- albuminuria, Macroalbuminuria, or serum type IV collagen concentrations in patients with diabetic nephropathy. Methods We studied 32 normotensive patients with type 2 diabetes mellitus associated with microalbuminuria (n = 16) or Macroalbuminuria (n = 16) and 20 healthy controls. The patients were randomly assigned to one of two groups: those treated with glibenclamide (5.0 mg/day) (n = 8) and those treated with troglitazone (400 mg/day) (n = 8). They received the drug regimen for 12 months. Serum type IV collagen was measured with sandwich enzyme immunoassay. Results Type IV collagen concentrations in macroalbuminuric patients were higher than those in microalbuminuric patients (P
-
effect of troglitazone on urinary albumin excretion and serum type iv collagen concentrations in type 2 diabetic patients with microalbuminuria or Macroalbuminuria
Diabetic Medicine, 2001Co-Authors: T. Nakamura, Chifuyu Ushiyama, Shigenobu Suzuki, N. Shimada, K. Sekizuka, L. Ebihara, Hikaru KoideAbstract:Summary Aims Troglitazone, a newly developed thiazolidinedione derivative, has been shown to ameliorate microalbuminuria in diabetic animal model and in human diabetic nephropathy in short-term studies. The aim of the present study was to determine whether troglitazone or sulphonylurea affect micro- albuminuria, Macroalbuminuria, or serum type IV collagen concentrations in patients with diabetic nephropathy. Methods We studied 32 normotensive patients with type 2 diabetes mellitus associated with microalbuminuria (n = 16) or Macroalbuminuria (n = 16) and 20 healthy controls. The patients were randomly assigned to one of two groups: those treated with glibenclamide (5.0 mg/day) (n = 8) and those treated with troglitazone (400 mg/day) (n = 8). They received the drug regimen for 12 months. Serum type IV collagen was measured with sandwich enzyme immunoassay. Results Type IV collagen concentrations in macroalbuminuric patients were higher than those in microalbuminuric patients (P < 0.05) and healthy controls (P < 0.01). Troglitazone reduced urinary albumin excretion (UAE) in micro- albuminuric patients from 126 μg/min (range 58–180 μg/min) to 42 μg/min (range 14–80 μg/min) (P < 0.01) and also reduced serum type IV collagen levels gradually at 3, 6 and 12 months after treatment (P < 0.05). However, glibenclamide did not affect UAE and type IV collagen levels in micro- albuminuric diabetes patients. In addition, neither troglitazone nor gliben- clamide changed UAE and type IV collagen levels in macroalbuminuric patients. Conclusions These data suggest that troglitazone is an effective treatment for renal injury in patients with early diabetic nephropathy.
Liffert Vogt - One of the best experts on this subject based on the ideXlab platform.
-
blood pressure lowering effects of sulodexide depend on albuminuria severity post hoc analysis of the sulodexide microalbuminuria and Macroalbuminuria studies
British Journal of Clinical Pharmacology, 2016Co-Authors: Rik H.g. Olde Engberink, Hiddo J.l. Heerspink, Dick De Zeeuw, Liffert VogtAbstract:Aims It has been suggested that sulodexide is able to lower blood pressure (BP). This may be attributed to its ability to restore the endothelial surface layer (ESL). As ESL perturbation is known to be related to the degree of kidney damage, we investigated whether albuminuria, reflecting ESL status, modified the BP-lowering potential of sulodexide. Methods A post hoc analysis of the double-blind, randomized, placebo-controlled sulodexide microalbuminuria (Sun-MICRO) and Macroalbuminuria (Sun-MACRO) studies, including 1056 microalbuminuric and 843 macroalbuminuric subjects with type 2 diabetes receiving maximal tolerated renin–angiotensin-aldosterone system inhibitor therapy, was carried out. We compared the effect of placebo and sulodexide on systolic BP (SBP) among albuminuria groups. Results Analysis of covariance, including data from both trials, showed that baseline urine albumin-to-creatinine ratio (UACR) was the only modifier of the SBP response (interaction with treatment P = 0.001). In subjects with an UACR >1000 mg g–1, sulodexide lowered SBP by 4.6 mmHg [95% confidence interval (CI) 3.6, 5.6; P < 0.001] compared with placebo, whereas a 2.3 mmHg (95% CI 0.9,3.7; P = 0.001) reduction was seen in subjects with a UACR of 300–1000 mg g–1. Sulodexide did not lower SBP in subjects with a UACR <300 mg g–1 (−0.2 mmHg, 95% CI −0.8, 0.5; P = 0.60). SBP-lowering effects were not accompanied by changes in body weight. Conclusion The BP-reducing potency of sulodexide is modified by the degree of albuminuria in subjects with type 2 diabetes. As ESL status deteriorates with increasing albuminuria and nephropathy severity, this suggests that ESL restoration may represent a new target for BP treatment in subjects with diabetic nephropathy.
-
Blood pressure-lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and Macroalbuminuria studies.
British Journal of Clinical Pharmacology, 2016Co-Authors: Rik H.g. Olde Engberink, Hiddo J.l. Heerspink, Dick De Zeeuw, Liffert VogtAbstract:Aims It has been suggested that sulodexide is able to lower blood pressure (BP). This may be attributed to its ability to restore the endothelial surface layer (ESL). As ESL perturbation is known to be related to the degree of kidney damage, we investigated whether albuminuria, reflecting ESL status, modified the BP-lowering potential of sulodexide. Methods A post hoc analysis of the double-blind, randomized, placebo-controlled sulodexide microalbuminuria (Sun-MICRO) and Macroalbuminuria (Sun-MACRO) studies, including 1056 microalbuminuric and 843 macroalbuminuric subjects with type 2 diabetes receiving maximal tolerated renin–angiotensin-aldosterone system inhibitor therapy, was carried out. We compared the effect of placebo and sulodexide on systolic BP (SBP) among albuminuria groups. Results Analysis of covariance, including data from both trials, showed that baseline urine albumin-to-creatinine ratio (UACR) was the only modifier of the SBP response (interaction with treatment P = 0.001). In subjects with an UACR >1000 mg g–1, sulodexide lowered SBP by 4.6 mmHg [95% confidence interval (CI) 3.6, 5.6; P
Chifuyu Ushiyama - One of the best experts on this subject based on the ideXlab platform.
-
Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or Macroalbuminuria.
Diabetic Medicine, 2001Co-Authors: T. Nakamura, Chifuyu Ushiyama, Shigenobu Suzuki, N. Shimada, K. Sekizuka, L. Ebihara, Hikaru KoideAbstract:Summary Aims Troglitazone, a newly developed thiazolidinedione derivative, has been shown to ameliorate microalbuminuria in diabetic animal model and in human diabetic nephropathy in short-term studies. The aim of the present study was to determine whether troglitazone or sulphonylurea affect micro- albuminuria, Macroalbuminuria, or serum type IV collagen concentrations in patients with diabetic nephropathy. Methods We studied 32 normotensive patients with type 2 diabetes mellitus associated with microalbuminuria (n = 16) or Macroalbuminuria (n = 16) and 20 healthy controls. The patients were randomly assigned to one of two groups: those treated with glibenclamide (5.0 mg/day) (n = 8) and those treated with troglitazone (400 mg/day) (n = 8). They received the drug regimen for 12 months. Serum type IV collagen was measured with sandwich enzyme immunoassay. Results Type IV collagen concentrations in macroalbuminuric patients were higher than those in microalbuminuric patients (P
-
effect of troglitazone on urinary albumin excretion and serum type iv collagen concentrations in type 2 diabetic patients with microalbuminuria or Macroalbuminuria
Diabetic Medicine, 2001Co-Authors: T. Nakamura, Chifuyu Ushiyama, Shigenobu Suzuki, N. Shimada, K. Sekizuka, L. Ebihara, Hikaru KoideAbstract:Summary Aims Troglitazone, a newly developed thiazolidinedione derivative, has been shown to ameliorate microalbuminuria in diabetic animal model and in human diabetic nephropathy in short-term studies. The aim of the present study was to determine whether troglitazone or sulphonylurea affect micro- albuminuria, Macroalbuminuria, or serum type IV collagen concentrations in patients with diabetic nephropathy. Methods We studied 32 normotensive patients with type 2 diabetes mellitus associated with microalbuminuria (n = 16) or Macroalbuminuria (n = 16) and 20 healthy controls. The patients were randomly assigned to one of two groups: those treated with glibenclamide (5.0 mg/day) (n = 8) and those treated with troglitazone (400 mg/day) (n = 8). They received the drug regimen for 12 months. Serum type IV collagen was measured with sandwich enzyme immunoassay. Results Type IV collagen concentrations in macroalbuminuric patients were higher than those in microalbuminuric patients (P < 0.05) and healthy controls (P < 0.01). Troglitazone reduced urinary albumin excretion (UAE) in micro- albuminuric patients from 126 μg/min (range 58–180 μg/min) to 42 μg/min (range 14–80 μg/min) (P < 0.01) and also reduced serum type IV collagen levels gradually at 3, 6 and 12 months after treatment (P < 0.05). However, glibenclamide did not affect UAE and type IV collagen levels in micro- albuminuric diabetes patients. In addition, neither troglitazone nor gliben- clamide changed UAE and type IV collagen levels in macroalbuminuric patients. Conclusions These data suggest that troglitazone is an effective treatment for renal injury in patients with early diabetic nephropathy.
Shigenobu Suzuki - One of the best experts on this subject based on the ideXlab platform.
-
Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or Macroalbuminuria.
Diabetic Medicine, 2001Co-Authors: T. Nakamura, Chifuyu Ushiyama, Shigenobu Suzuki, N. Shimada, K. Sekizuka, L. Ebihara, Hikaru KoideAbstract:Summary Aims Troglitazone, a newly developed thiazolidinedione derivative, has been shown to ameliorate microalbuminuria in diabetic animal model and in human diabetic nephropathy in short-term studies. The aim of the present study was to determine whether troglitazone or sulphonylurea affect micro- albuminuria, Macroalbuminuria, or serum type IV collagen concentrations in patients with diabetic nephropathy. Methods We studied 32 normotensive patients with type 2 diabetes mellitus associated with microalbuminuria (n = 16) or Macroalbuminuria (n = 16) and 20 healthy controls. The patients were randomly assigned to one of two groups: those treated with glibenclamide (5.0 mg/day) (n = 8) and those treated with troglitazone (400 mg/day) (n = 8). They received the drug regimen for 12 months. Serum type IV collagen was measured with sandwich enzyme immunoassay. Results Type IV collagen concentrations in macroalbuminuric patients were higher than those in microalbuminuric patients (P
-
effect of troglitazone on urinary albumin excretion and serum type iv collagen concentrations in type 2 diabetic patients with microalbuminuria or Macroalbuminuria
Diabetic Medicine, 2001Co-Authors: T. Nakamura, Chifuyu Ushiyama, Shigenobu Suzuki, N. Shimada, K. Sekizuka, L. Ebihara, Hikaru KoideAbstract:Summary Aims Troglitazone, a newly developed thiazolidinedione derivative, has been shown to ameliorate microalbuminuria in diabetic animal model and in human diabetic nephropathy in short-term studies. The aim of the present study was to determine whether troglitazone or sulphonylurea affect micro- albuminuria, Macroalbuminuria, or serum type IV collagen concentrations in patients with diabetic nephropathy. Methods We studied 32 normotensive patients with type 2 diabetes mellitus associated with microalbuminuria (n = 16) or Macroalbuminuria (n = 16) and 20 healthy controls. The patients were randomly assigned to one of two groups: those treated with glibenclamide (5.0 mg/day) (n = 8) and those treated with troglitazone (400 mg/day) (n = 8). They received the drug regimen for 12 months. Serum type IV collagen was measured with sandwich enzyme immunoassay. Results Type IV collagen concentrations in macroalbuminuric patients were higher than those in microalbuminuric patients (P < 0.05) and healthy controls (P < 0.01). Troglitazone reduced urinary albumin excretion (UAE) in micro- albuminuric patients from 126 μg/min (range 58–180 μg/min) to 42 μg/min (range 14–80 μg/min) (P < 0.01) and also reduced serum type IV collagen levels gradually at 3, 6 and 12 months after treatment (P < 0.05). However, glibenclamide did not affect UAE and type IV collagen levels in micro- albuminuric diabetes patients. In addition, neither troglitazone nor gliben- clamide changed UAE and type IV collagen levels in macroalbuminuric patients. Conclusions These data suggest that troglitazone is an effective treatment for renal injury in patients with early diabetic nephropathy.
